Nexalin Technology, Inc.
About Nexalin Technology, Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $301.6K
- Net income
- -$8.2M
- Total assets
- $4.6M
- Market cap
- $11.3M
- Gross margin
- 79.7%
- Operating margin
- -2781.7%
- Net margin
- -2725.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $301.6K
- Cost of revenue
- $61.4K
- Gross profit
- $240.3K
- Operating expenses
- $8.6M
- Operating income
- -$8.4M
- Net income
- -$8.2M
- EPS (basic)
- $-0.50
- EPS (diluted)
- $-0.50
Balance sheet
- Total assets
- $4.6M
- Current assets
- $4.3M
- Total liabilities
- $887.3K
- Current liabilities
- $887.3K
- Shareholders’ equity
- $3.7M
Cash flow
- Operating cash flow
- -$5.0M
- Investing cash flow
- -$132.0K
- Financing cash flow
- $5.2M
- Net cash flow
- $80.3K
Statements via Polygon.io (SEC filings)
- Market cap
- $11.3M
- EPS (diluted)
- $-0.5
- Dividend yield
- 250.0%
- Shares outstanding
- 22.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 16, 2022
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $8.2M in FY2025.
- Revenue declined 77% from FY2022 to FY2025.
- Gross margin of 79.7%, net margin -2725.8%.
- Trading 73% below its 52-week high.
- Pays a dividend yielding about 250.0% annually.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Nexalin Technology, Inc..
Write a review
News about Nexalin Technology, Inc.
News & sentiment via Polygon.io
